Table 3 Impact of baseline patient characteristics on potency rates two years post-SBRT
From: Potency preservation following stereotactic body radiation therapy for prostate cancer
| Characteristics | % Potent 2 years after SBRT | p value | |
|---|---|---|---|
| Age | |||
| ≤ 65 y/o pre-RT | 66.7% | 0.580 | |
| >65 y/o pre-RT | 47.4% | ||
| Race | |||
| White | 51.2% | 0.574 | |
| Non-white | 57.4% | ||
| Partner status | |||
| Partnered | 54.3% | 0.297 | |
| Non-partnered | 55.0% | ||
| Charlson comorbidity index (CCI) | |||
| 0 | 58.9% | 0.007* | |
| ≥1 | 35.3% | ||
| Body mass index (BMI) | |||
| < 30 | 60.9% | 0.943 | |
| ≥ 30 | 38.5% | ||
| Risk group (D’ Amico’ s) | |||
| Low risk | 54.8% | 0.420 | |
| Intermediate-High Risk | 54.2% | ||
| Work status | |||
| Working | 54.7% | 0.173 | |
| Non-working | 54.1% | ||
| Pre- treatment SHIM | |||
| ≥ 22 | 40.91% | 0.127 | |
| < 22 | 67.39% | ||
| Sexual aid | |||
| None | 43.8% | 0.010*# | |
| Yes | 60.3% | ||
| SBRT Dose | |||
| 36.25 Gy | 50.0% | 0.933 | |
| < 36.25 Gy | 55.0% | ||